---
id: antimicrobials_tmp-smx-nocardia_023
category: antimicrobials
tags: [antimicrobials, tmp-smx, nocardia, duration, CNS]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## TMP-SMX for Nocardia Treatment

**Q:** What is the first-line treatment for Nocardia, and how does treatment duration vary by site and host?

**A:**

**First-Line Agent:** **TMP-SMX** (drug of choice)

**Dosing:**
- **10-15 mg/kg/day** (based on TMP component) divided BID-TID
- Recent 2024 evidence: Low-to-intermediate doses may be adequate for **isolated pulmonary** disease (historically used high-dose may not be necessary)
- Check TMP levels if available (target: 5-10 µg/mL)

**Treatment Duration by Site:**

| **Site** | **Immunocompetent** | **Immunocompromised** |
|----------|---------------------|------------------------|
| **Pulmonary (localized)** | 6-12 months | 12 months |
| **Disseminated (non-CNS)** | 6-12 months | ≥12 months |
| **CNS involvement** | ≥12 months | ≥12 months |

**Key Points:**
- **CNS disease:** ALWAYS treat ≥12 months regardless of immune status
- **Combination therapy** recommended for:
  - Immunocompromised patients
  - Disseminated disease
  - Add: amikacin, imipenem, or meropenem until susceptibilities available
  - Continue IV for 3-6 weeks until clinical improvement before switching to PO

**Alternative Agents:**
- Linezolid (good CNS penetration)
- Amikacin (synergistic with TMP-SMX)
- Carbapenems (imipenem, meropenem)
- Ceftriaxone

**Mnemonic: "NOcardia needs a LONG time"**
- **N**eed 6-12 months minimum
- **O**ne year for CNS (12 months)
- **L**onger if immunocompromised
- **O**bserve clinical improvement before PO switch
- **N**ever stop early (relapses common)
- **G**ive combo therapy if severe

**Media:** None

**Sources:** [Medscape Nocardiosis 2024], [Infection 2024 - TMP-SMX dosing outcomes], [PMC 2012 - Nocardiosis updates], [JWATCH 2024 - High vs low dose]
